BMO Capital Reiterates Outperform Rating on Novo Nordisk (NVO) Amid Solid SubQ Amycretin Results

BMO Capital analyst Evan Seigerman reiterated an Outperform rating and $105.00 price target on Novo Nordisk (NYSE: NVO) following SubQ amycretin results.

The analyst commented, "Results for Novo's SubQ amycretin likely outperform investor expectations, resetting the longer term narrative for Novo shares with a viable next gen asset. SubQ amycretin, outperformed what we have previously seen from CagriSema with a placebo-adjusted weight loss of 24.0% at the 20mg dose at 36 weeks. Though we look to later trials to confirm, SubQ amycretin has the potential to reach a new high watermark for weight loss, providing Novo a viable next gen asset and simplifying the manufacturing concerns of CagriSema with a single chamber pen"

For an analyst ratings summary and ratings history on Novo Nordisk click here. For more ratings news on Novo Nordisk click here.

Shares of Novo Nordisk closed at $81.10 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• Phillips 66, Marathon Merger Talks Collapsed - Semafor